{"id":556512,"date":"2021-08-06T14:40:01","date_gmt":"2021-08-06T14:40:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556512"},"modified":"2021-08-06T14:40:01","modified_gmt":"2021-08-06T14:40:01","slug":"levodopainduced-dyskinesia-market-insight-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/levodopainduced-dyskinesia-market-insight-epidemiology-and-market-forecast-2030_556512.html","title":{"rendered":"Levodopa-Induced Dyskinesia Market Insight, Epidemiology And Market Forecast -2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Levodopa-Induced Dyskinesia Market Insight, Epidemiology And Market Forecast -2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Levodopa-Induced Dyskinesia Market Insight, Epidemiology And Market Forecast -2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Levodopa-Induced Dyskinesia Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Levodopa-Induced Dyskinesia (LID), historical and forecasted epidemiology as well as the Levodopa-Induced Dyskinesia (LID) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/dailyresearchsheets.com\/wp-content\/uploads\/2021\/07\/Levodopa-Induced-Dyskinesia.jpg\" alt=\"Levodopa-Induced-Dyskinesia\" width=\"750\" height=\"410\" \/><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<span>Levodopa-Induced Dyskinesia (LID) Market Insights<\/span>&rdquo; report delivers an in-depth understanding of the Levodopa-Induced Dyskinesia (LID), historical and forecasted epidemiology as well as the Levodopa-Induced Dyskinesia (LID) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">The Levodopa-Induced Dyskinesia (LID) market report provides current treatment practices, emerging drugs, Levodopa-Induced Dyskinesia (LID) market share of the individual therapies, current and forecasted Levodopa-Induced Dyskinesia (LID) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Levodopa-Induced Dyskinesia (LID) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\"><span>Levodopa-Induced Dyskinesia Market Outlook<\/span><\/p>\n<p style=\"text-align: justify;\">According to DelveInsight,&nbsp;<span>Levodopa-Induced Dyskinesia (LID)&nbsp;market<\/span>&nbsp;in 7MM is expected to change in the study period 2017-2030.<\/p>\n<p style=\"text-align: justify;\">The&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/levodopa-induced-dyskinesia-lid-market\"><span>Levodopa-Induced Dyskinesia market outlook<\/span><\/a>&nbsp;of the report helps to build the detailed comprehension of the historic, current, and forecasted Levodopa-Induced Dyskinesia (LID)<span>&nbsp;<\/span>market<span>&nbsp;<\/span>trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.<\/p>\n<p style=\"text-align: justify;\">This segment gives a thorough detail of Levodopa-Induced Dyskinesia (LID)<span>&nbsp;<\/span>market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria&rsquo;s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\">To know more, request sample pages of&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/levodopa-induced-dyskinesia-lid-market\"><span>Levodopa-Induced Dyskinesia Market<\/span><\/a><span>&nbsp;@&nbsp;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/levodopa-induced-dyskinesia-lid-market\"><span>https:\/\/www.delveinsight.com\/report-store\/levodopa-induced-dyskinesia-lid-market<\/span><\/a><\/p>\n<p style=\"text-align: justify;\"><span>Scope of the Report<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Levodopa-Induced Dyskinesia (LID), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Levodopa-Induced Dyskinesia (LID) epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Levodopa-Induced Dyskinesia (LID) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Levodopa-Induced Dyskinesia (LID) market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Levodopa-Induced Dyskinesia (LID) market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>Report Highlights<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>In the coming years, Levodopa-Induced Dyskinesia (LID) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market<\/li>\n<li>The companies and academics are working to assess challenges and seek opportunities that could influence Levodopa-Induced Dyskinesia (LID) R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition<\/li>\n<li>Major players are involved in developing therapies for Levodopa-Induced Dyskinesia (LID). Launch of emerging therapies will significantly impact the Levodopa-Induced Dyskinesia (LID) market<\/li>\n<li>A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Levodopa-Induced Dyskinesia (LID)<\/li>\n<li>Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span>Table of contents<\/span><\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Levodopa-Induced Dyskinesia (LID)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Competitive Intelligence Analysis for Levodopa-Induced Dyskinesia (LID)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Levodopa-Induced Dyskinesia (LID): Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Levodopa-Induced Dyskinesia (LID) Total Market Share (%) Distribution in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Levodopa-Induced Dyskinesia (LID) Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\"><span>5. Levodopa-Induced Dyskinesia (LID): Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2. Sign and Symptoms<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3. Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4. Risk Factors<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5. Diagnosis<\/p>\n<p style=\"text-align: justify;\"><span>6. Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7. Levodopa-Induced Dyskinesia (LID) Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.1.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.2.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in France (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.3.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.4.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.5.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.6.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><span>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1. Levodopa-Induced Dyskinesia (LID) Treatment and Management<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2. Levodopa-Induced Dyskinesia (LID) Treatment Algorithm<\/p>\n<p style=\"text-align: justify;\"><span>9. Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Key Endpoints of Levodopa-Induced Dyskinesia (LID) Treatment<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Marketed Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><span>12. Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><span>13. Levodopa-Induced Dyskinesia (LID): Seven Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Levodopa-Induced Dyskinesia (LID) Market Size in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\"><span>14. Attribute analysis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15. 7MM: Market Outlook<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.1. Levodopa-Induced Dyskinesia (LID) Total Market Size in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.2. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1. Levodopa-Induced Dyskinesia (LID) Total Market Size in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.1. Levodopa-Induced Dyskinesia (LID) Total Market Size in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.2. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.1. Levodopa-Induced Dyskinesia (LID) Total Market Size in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.2. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.1. Levodopa-Induced Dyskinesia (LID) Total Market Size in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.2. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.1. Levodopa-Induced Dyskinesia (LID) Total Market Size in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.2. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in the United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.2. Levodopa-Induced Dyskinesia (LID) Total Market Size in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.3. Levodopa-Induced Dyskinesia (LID) Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><span>16. Access and Reimbursement Overview of Levodopa-Induced Dyskinesia (LID)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><span>21. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>22. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>23. About DelveInsight<\/span><\/p>\n<p style=\"text-align: justify;\"><span><em>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/em><\/span><\/p>\n<p style=\"text-align: justify;\">Request sample pages for more information on&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/levodopa-induced-dyskinesia-lid-market\"><span>Levodopa-Induced Dyskinesia Market<\/span><\/a><span>&nbsp;@&nbsp;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/levodopa-induced-dyskinesia-lid-market\"><span>https:\/\/www.delveinsight.com\/sample-request\/levodopa-induced-dyskinesia-lid-market<\/span><\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=levodopainduced-dyskinesia-market-insight-epidemiology-and-market-forecast-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=levodopainduced-dyskinesia-market-insight-epidemiology-and-market-forecast-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Levodopa-Induced Dyskinesia Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Levodopa-Induced Dyskinesia (LID), historical and forecasted epidemiology as well as the Levodopa-Induced Dyskinesia (LID) market trends in the United States, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/levodopainduced-dyskinesia-market-insight-epidemiology-and-market-forecast-2030_556512.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-556512","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556512"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556512\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}